Stromal gene signatures in large-B-cell lymphomas.

ABSTRACT:

Background

The addition of rituximab to combination chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), or R-CHOP, has significantly improved the survival of patients with diffuse large-B-cell lymphoma. Whether gene-expression signatures correlate with survival after treatment of diffuse large-B-cell lymphoma is unclear.

Methods

We profiled gene expression in pretreatment biopsy specimens from 181 patients with diffuse large-B-cell lymphoma who received CHOP and 233 patients with this disease who received R-CHOP. A multivariate gene-expression-based survival-predictor model derived from a training group was tested in a validation group.

Results

A multivariate model created from three gene-expression signatures--termed "germinal-center

SUBMITTER: Lenz G 

PROVIDER: S-EPMC9103713 | biostudies-literature | 2008 Nov

REPOSITORIES: biostudies-literature